RK Pharma Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2040
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Storage-stable ready-to-use formulations of tigecycline (US 11,654,151) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Ready to use injectable formulations of melphalan and processes for preparation thereof (US 11,857,677) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,260,065 | Storage-stable ready-to-use injectable formulations of thiotepa In force · From the USPTO record | In force | From the USPTO record | |
| US 11,111,208 | Process for the preparation of safinamide mesylate intermediate In force · From the USPTO record | In force | From the USPTO record | |
| US 11,332,495 | Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix In force · From the USPTO record | In force | From the USPTO record | |
| US 12,215,234 | Process for the purification of methylene blue In force · From the USPTO record | In force | From the USPTO record | |
| US 11,857,677 | Ready to use injectable formulations of melphalan and processes for preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,654,151 | Storage-stable ready-to-use formulations of tigecycline In force · From the USPTO record | In force | From the USPTO record | |
| US 12,396,999 | Composition of ferric maltol for oral administration In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 7: 4 patents in force now held by others · 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 3 no status recorded